Results 1 to 10 of about 8,401 (177)

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients [PDF]

Nature Communications
Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 symptoms randomised to receive molnupiravir (n = 253) or Usual Care (n = 
Joseph F. Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, Maximillian Woodall, Samuel Ellis, Akosua A. Agyeman, Charles Miller, Mercy Okechukwu, Emily Kirkpatrick, Amy I. Jacobs, Charlotte A. Williams, Sunando Roy, Luz M. Martin-Bernal, Rachel Williams, Claire M. Smith, Theo Sanderson, Fiona B. Ashford, Beena Emmanuel, Zaheer M. Afzal, Adrian Shields, Alex G. Richter, Jienchi Dorward, Oghenekome Gbinigie, Oliver Van Hecke, Mark Lown, Nick Francis, Bhautesh Jani, Duncan B. Richards, Najib M. Rahman, Ly-Mee Yu, Nicholas P. B. Thomas, Nigel D. Hart, Philip Evans, Monique Andersson, Gail Hayward, Kerenza Hood, Jonathan S. Nguyen-Van-Tam, Paul Little, F. D. Richard Hobbs, Saye Khoo, Christopher Butler, David M. Lowe, Judith Breuer, PANORAMIC Virology Group   +43 more
doaj   +11 more sources

Use of molnupiravir:A Danish nationwide drug utilization study [PDF]

Pharmacoepidemiology and Drug Safety, 2023
Purpose: To describe utilization patterns, characteristics of users and prescribers of the new oral antiviral medication, molnupiravir, indicated for mild-to-moderate COVID-19.
Hallas, Jesper, Jensen, Peter Bjødstrup, Ladebo, Louise, Lindahl, Mette, Rasmussen, Lotte, Reilev, Mette, Øvrehus, Anne   +6 more
core   +3 more sources

Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry [PDF]

Antibiotics, 2022
Real-life experience of molnupiravir treatment is lacking, especially in people hospitalized for underlying diseases not related to COVID-19. We conducted a retrospective analysis regarding molnupiravir therapy in patients with SARS-CoV-2 infection ...
Tommaso Lupia, Silvia Corcione, Nour Shbaklo, Lucio Boglione, Stefano Torresan, Simone Mornese Pinna, Barbara Rizzello, Roberta Bosio, Valentina Fornari, Maria Teresa Brusa, Silvio Borrè, Francesco Giuseppe De Rosa   +11 more
doaj   +4 more sources

SARS-CoV-2 Error Catastrophe Under Molnupiravir: Mutagenic Enhancement Enables Viral Persistence with Impaired Fitness [PDF]

Viruses
Molnupiravir induces mutations that render severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication-competent through error catastrophe mechanisms.
Yuriko Tomita, Kaya Miyazaki, Rika Mochizuki, Hideki Hasegawa   +3 more
doaj   +2 more sources

Effectiveness comparison of nirmatrelvir/ritonavir versus molnupiravir in COVID-19 patients with comorbidities in Taiwan: a multi-centre electronic health record study [PDF]

BMC Infectious Diseases
Background COVID-19 patients frequently present with various comorbidities. Two developed antiviral medications, nirmatrelvir/ritonavir and molnupiravir, have been utilized in COVID-19 patients; but comparisons of the effectiveness between nirmatrelvir ...
Wen-Kuang Lin, Shwu-Jiuan Lin, Yu-Hui Chang, Fu-Der Wang, Phung-Anh Nguyen, Phan Thanh Phuc, Whitney Burton, Nguyen Thi Kim Hien, Chia-Chieh Lin, Carlos Shu-Kei Lam, To-Chi Ha, Christine Y. Lu, Chih-Wei Huang, Hsuan-Chia Yang, Shiue-Ming Lin, Chieh Yang, Li-Hsuan Wang, Jason C. Hsu   +17 more
doaj   +2 more sources

Molnupiravir Inhibits Replication of Multiple Alphacoronavirus suis Strains in Feline Cells [PDF]

Pathogens
The cross-species spillover of coronaviruses is considered a serious public health risk. Feline coronavirus (FCoV), canine coronavirus (CCoV), and transmissible gastroenteritis virus (TGEV) are all classified under Alphacoronavirus suis and infect ...
Tomoyoshi Doki, Kazuki Shinohara, Kaito To, Tomomi Takano   +3 more
doaj   +2 more sources

Why Molnupiravir Fails in Hospitalized Patients

mBio, 2022
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has radically altered daily life.
Ashley N. Brown, Yinzhi Lang, Jieqiang Zhou, Evelyn J. Franco, Kaley C. Hanrahan, Juergen B. Bulitta, George L. Drusano   +6 more
doaj   +3 more sources

A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration. [PDF]

J Infect Dis
Background The antiviral efficacy of molnupiravir against SARS-CoV-2 is controversial. Here, we develop a model integrating viral and immune dynamics to characterize the mechanism of action of molnupiravir in vivo and its impact on viral dynamics during ...
Nguyen BT, Bertrand J, Agyeman AA, Zhang S, Yu LM, Harris V, Little P, Butler CC, Breuer J, Lowe DM, Standing JF, Guedj J, PANORAMIC study group .   +12 more
europepmc   +4 more sources

Molnupiravir inhibits Bourbon virus infection and disease-associated pathology in mice [PDF]

Journal of Virology
Bourbon virus (BRBV) is an emerging tick-borne virus that can cause severe and fatal disease in humans. BRBV is vectored via the Amblyomma americanum tick, which is widely distributed throughout the central, eastern, and southern United States ...
Gayan Bamunuarachchi, Fang R. Zhao, Traci L. Bricker, Kuljeet Seehra, Andrew Karp, Michael S. Diamond, Adrianus C. M. Boon   +6 more
doaj   +2 more sources

Prevention is better than healing. Clinical and economic implications of oral antiviral agents in COVID-19: a prospective study [PDF]

Italian Journal of Medicine
COVID-19 represents a threat for frailty patients. This study compares molnupiravir and nirmatrelvir for fragile COVID- 19 patients' efficacy, safety, and cost.
Filomena Pietrantonio, Francesco Rosiello, Matteo Ruggeri, Maria Sofia Cattaruzza, Antonio Vinci, Margherita Lordi, Enrica Cipriano   +6 more
doaj   +3 more sources